Table 5.
Summary of efficacy results for patients with idiopathic hypotrichosis treated with bimatoprost in treatment period 1 and switched to vehicle in treatment period 2 (intent‐to‐treat population)
| Efficacy variable)/visita | Treatment | Primary composite end point (n = 60) | ≥ 1‐grade improvement from baseline GEA score (n = 60) | ≥ 3‐point improvement from baseline ESQ Domain 2 score (n = 60) | ≥ 2‐grade improvement from baseline GEA score (n = 60) |
|---|---|---|---|---|---|
| Month 1 | Bimatoprost | 0 (0·0) | 6 (10·0) | 8 (13·3) | 0 (0·0) |
| Month 2 | 8 (13·3) | 24 (40·0) | 15 (25·0) | 2 (3·3) | |
| Month 4 | 25 (41·7) | 43 (71·7) | 29 (48·3) | 15 (25·0) | |
| Month 6 | 29 (48·3) | 46 (76·7) | 34 (56·7) | 18 (30·0) | |
| Month 7 | Vehicle | 31 (51·7) | 47 (78·3) | 34 (56·7) | 18 (30·0) |
| Month 8 | 30 (50·0) | 47 (78·3) | 33 (55·0) | 17 (28·3) | |
| Month 10 | 12 (20·0) | 28 (46·7) | 26 (43·3) | 5 (8·3) | |
| Month 12 | 7 (11·7) | 21 (35·0) | 23 (38·3) | 3 (5·0) |
Values given as n (%). Bimatoprost, bimatoprost ophthalmic solution 0·03%; GEA, Global Eyelash Assessment; ESQ, Eyelash Satisfaction Questionnaire. aVisit was based on visit window. Baseline was defined as the most recent evaluation prior to day 1. Last observation carried forward was performed.